# Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients

> **NCT02744209** · — · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 17 (actual)

## Conditions studied

- Stage IV Melanoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02744209
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04
- **Primary completion:** 2019-01
- **Final completion:** 2019-01
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2019-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02744209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02744209, "Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02744209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*